Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated:  3/15/2016
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated: 3/15/2016
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated:  3/15/2016
Oncology Consultants
mi
from
Houston, TX
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated: 3/15/2016
Oncology Consultants
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated:  3/15/2016
Texas Oncology - McAllen
mi
from
McAllen, TX
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated: 3/15/2016
Texas Oncology - McAllen
mi
from
McAllen, TX
Click here to add this to my saved trials
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated:  3/15/2016
Texas Oncology-Tyler
mi
from
Tyler, TX
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated: 3/15/2016
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated:  3/15/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated: 3/15/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated:  3/15/2016
Univ of Washington
mi
from
Seattle, WA
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated: 3/15/2016
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated:  3/15/2016
Virginia Mason Medical Center
mi
from
Seattle, WA
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated: 3/15/2016
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated:  3/15/2016
Krankenhaus der Elisabethinen Linz
mi
from
Linz,
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Status: Enrolling
Updated: 3/15/2016
Krankenhaus der Elisabethinen Linz
mi
from
Linz,
Click here to add this to my saved trials
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
Phase II Study of Interleukin- 2 and Bevacizumab in Patients With Progressive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
Phase II Study of Interleukin- 2 and Bevacizumab in Patients With Progressive Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  3/15/2016
Methodist Hospital - Baylor College of Medicine
mi
from
Houston, TX
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 3/15/2016
Methodist Hospital - Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Interferon Alfa (IFN-α) on Patients With Advanced or Metastatic Renal Cell Cancer
Status: Enrolling
Updated:  3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Interferon Alfa (IFN-α) on Patients With Advanced or Metastatic Renal Cell Cancer
Status: Enrolling
Updated: 3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer
Phase II Study of RAD001 (Everolimus) in Patient's With Metastatic Renal Cell Cancer
Status: Enrolling
Updated:  3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer
Phase II Study of RAD001 (Everolimus) in Patient's With Metastatic Renal Cell Cancer
Status: Enrolling
Updated: 3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
Phase I/II Trial of RAD001 Plus Nexavar® For Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  3/15/2016
The Methodist Hospital Research Institute
mi
from
Houston, TX
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
Phase I/II Trial of RAD001 Plus Nexavar® For Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 3/15/2016
The Methodist Hospital Research Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
A Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
A Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 3/15/2016
Baylor College of Medicine/The Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123
Status: Enrolling
Updated:  3/15/2016
University of Florida
mi
from
Gainesville, FL
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123
Status: Enrolling
Updated: 3/15/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123
Status: Enrolling
Updated:  3/15/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123
Status: Enrolling
Updated: 3/15/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123
Status: Enrolling
Updated:  3/15/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123
Status: Enrolling
Updated: 3/15/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123
Status: Enrolling
Updated:  3/15/2016
Baylor College of Medicine
mi
from
Houston, TX
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123
Status: Enrolling
Updated: 3/15/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123
Status: Enrolling
Updated:  3/15/2016
St. Bartholomew's Hospital (Barts)
mi
from
London,
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123
Status: Enrolling
Updated: 3/15/2016
St. Bartholomew's Hospital (Barts)
mi
from
London,
Click here to add this to my saved trials
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis
Status: Enrolling
Updated:  3/16/2016
Boston University Cancer Research Center
mi
from
Boston, MA
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis
Status: Enrolling
Updated: 3/16/2016
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma
Status: Enrolling
Updated:  3/16/2016
Ohio State University
mi
from
Columbus, OH
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma
Status: Enrolling
Updated: 3/16/2016
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Southern Cancer Center
mi
from
Mobile, AL
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Southern Cancer Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Alaska Clinical Research Center, LLC
mi
from
Anchorage, AK
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Alaska Clinical Research Center, LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Marsha G. Fink, Md, Inc.
mi
from
Fountain Valley, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Marsha G. Fink, Md, Inc.
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
VA San Diego Healthcare System
mi
from
San Diego, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
VA San Diego Healthcare System
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Pacific Hematology Oncology Associates
mi
from
San Francisco, CA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Pacific Hematology Oncology Associates
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Baptist Cancer Institute
mi
from
Jacksonville, FL
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Baptist Cancer Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Suburban Hematology/Oncology Associates, Pc
mi
from
Lawrenceville, GA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Suburban Hematology/Oncology Associates, Pc
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
University of Chicago
mi
from
Chicago, IL
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Cancer Care Specialists of Central Illinois
mi
from
Decatur, IL
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Cancer Care Specialists of Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Edward Cancer Center
mi
from
Naperville, IL
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Edward Cancer Center
mi
from
Naperville, IL
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Mid-Illinois Hematology & Oncology Associates, Ltd
mi
from
Normal, IL
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Mid-Illinois Hematology & Oncology Associates, Ltd
mi
from
Normal, IL
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Siouxland Hematology-Oncology Assoc., Llp
mi
from
Sioux City, IA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Siouxland Hematology-Oncology Assoc., Llp
mi
from
Sioux City, IA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Hutchinson Clinic
mi
from
Hutchinson, KA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Hutchinson Clinic
mi
from
Hutchinson, KA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Kentucky Cancer Clinic
mi
from
Hazard, KY
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Kentucky Cancer Clinic
mi
from
Hazard, KY
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
The Bunting-Blaustein Cancer Research Building
mi
from
Baltimore, MD
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
The Bunting-Blaustein Cancer Research Building
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Frederick Memorial Hospital Regional Cancer Therapy Center
mi
from
Frederick, MD
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Frederick Memorial Hospital Regional Cancer Therapy Center
mi
from
Frederick, MD
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Kansas City Veterans Affairs Medical Center
mi
from
Kansas City, MO
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Kansas City Veterans Affairs Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
St John's Medical Research Institute
mi
from
Springfield, MO
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
St John's Medical Research Institute
mi
from
Springfield, MO
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Raleigh Hematology Oncology Associates
mi
from
Raleigh, NC
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Raleigh Hematology Oncology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
University of Cincinnati
mi
from
Cincinnati, OH
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated:  3/16/2016
Providence Portland Medical Center
mi
from
Portland, OR
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel
Status: Enrolling
Updated: 3/16/2016
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials